抑制SRD5A1与BRD4抑制剂结合,通过降低AR表达来延缓前列腺癌的进展
Yifan Liu1, Duocheng Qian2, Yifan Ding1
1Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, China.
International journal of biological macromolecules
|December 21, 2025
概括
准SRD5A1和BRD4为前列腺癌 (PCa) 提供了一个新的策略. 抑制这些标会降低雄激素受体 (AR) 表达,可能阻止PCa的进展,克服药物耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 前列腺癌 (PCa) 发病率和死亡率随着预期寿命的增加而上升.
- 雄激素剥夺疗法 (ADT) 是有效的,但面临药物耐药性挑战.
- 表观遗传阅读器BRD4调节了安卓代谢中的关键酶,这对PCa进展至关重要.
研究的目的:
- 调查SRD5A1在PCa进展中的作用.
- 评估PCa中抑制SRD5A1和BRD4的疗效.
- 探索用于PCa中增强AR抑制的组合疗法.
主要方法:
- 生物信息分析以确定BRD4.4的SRD5A1调节.
- 在体外研究中使用PCa细胞系与BRD4抑制剂 (JQ1,I-BET151) 和SRD5A1抑制剂 (dutasteride).
- 评估SRD5A1在促进AR活性和二二 (DHT) 水平方面的机制.
主要成果:
- BRD4 抑制剂 (JQ1,I-BET151) 降低了PCa细胞中的SRD5A1表达.
- 通过杜塔胺抑制SRD5A1减少了PCa细胞的增殖和侵入.
- 发现SRD5A1通过增加细胞内DHT来增强AR活性,从而促进AR表达和瘤发生.
- BRD4和SRD5A1都调节AR表达,联合抑制显示出更大的抑制.
结论:
- 通过调节AR活性,SRD5A1在前列腺癌的进展中发挥着关键作用.
- 联合抑制BRD4和SRD5A1是一种有希望的治疗策略,可以抑制AR表达并阻止PCa的发展.
- 这种组合方法可以克服与当前的治疗方法 (如ADT) 相关的耐药性.
相关概念视频
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Negative Regulator Molecules
38.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.2K
The Retinoblastoma Gene
4.6K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.3K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
879
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
879


